2024
Reasons for screening failure in the evoke and evoke+ trials of semaglutide for early AD
Sano M, Cummings J, Feldman H, Hansson O, van der Flier W, Bardtrum L, Jeppesen R, Johannsen P, LĂ©on T, Hansen C, Scheltens P. Reasons for screening failure in the evoke and evoke+ trials of semaglutide for early AD. Alzheimer's & Dementia 2024, 20: e088735. PMCID: PMC11713595, DOI: 10.1002/alz.088735.Peer-Reviewed Original ResearchMini-Mental State ExaminationAmyloid positivityStrategic infarctsMild AD dementiaRepeatable BatteryPsychiatric disordersCognitive Assessment scoreMild cognitive impairment due to ADInclusion of participantsCognitive impairment due to ADCognitive scoresMini-MentalState ExaminationCDR scoreNeurological disordersScreening failureDisordersEvidence of neurologic disordersAD dementiaScreening failure rateSmall vessel pathologyEvokedScoresCentral nervous systemHierarchical screening procedure
2023
Stable Isotope Labelling Kinetics: Models and methods to evaluate APP production rates with Posiphen treatment in the DISCOVER clinical trial
Elbert D, Galasko D, Farlow M, Aslanyan V, Pa J, Lucey B, Honig L, Moghekar A, Bateman R, Momper J, Rissman R, Balasubramanian A, Maccecchini M, Feldman H, Group A. Stable Isotope Labelling Kinetics: Models and methods to evaluate APP production rates with Posiphen treatment in the DISCOVER clinical trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.077287.Peer-Reviewed Original ResearchAβ40 concentrationsBeta-amyloid precursor protein (APP) mRNAAmyloid precursor protein (APP) mRNASequential dose cohortsHigh-dose groupMild AD dementiaPrecursor protein mRNADose cohortsVenous cathetersStudy armsAD dementiaDose groupDrug exposureVenous bloodPosiphenAβ kineticsDay 22Therapeutic potentialPlaceboDecreased productionGroup differencesPatientsPharmacodynamicsFurther clarificationHours
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply